Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations
- PMID: 26152440
- PMCID: PMC6077843
- DOI: 10.3122/jabfm.2015.04.150062
Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations
Abstract
Purpose: To assess changes of prostate-specific antigen (PSA) testing following recent US Preventive Services Task Force (USPSTF) prostate cancer screening recommendations using 2005 to 2013 National Health Interview Survey data.
Methods: We calculated the percentage of PSA testing among men ≥40 years by age group and age-adjusted race for each survey year. Differences between years were assessed with linear contrasts after combining all years' data.
Results: The overall percentage of PSA testing was highest in 2008 and decreased significantly in 2013. Compared with 2008, each age group had significantly lower screening percentages in 2013, especially men ≥75 years old (-14.0% points; P < .001). Both men aged 50 to 74 and men aged ≥75 had significantly lower percentages in 2013 than in 2010. For white and black men, the PSA testing percentages were highest in 2008 and decreased significantly in 2013. Only white men had a significantly lower percentage in 2013 than in 2010.
Conclusions: Significant declines in PSA testing from 2008 to 2013 in men ≥75 years old may reflect the impact of the 2008 USPSTF recommendations. While the cause of the decreases in PSA testing between 2010 and 2013 among men aged 50 to 74 years old and white men is unknown, the decreases may suggest the early effects of the 2012 recommendations.
Keywords: Cancer Screening; Prostate Cancer; Prostate-Specific Antigen.
© Copyright 2015 by the American Board of Family Medicine.
Conflict of interest statement
Figures
Similar articles
-
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.J Clin Oncol. 2015 Aug 1;33(22):2416-23. doi: 10.1200/JCO.2015.61.6532. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056181
-
Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.Urol Oncol. 2014 Jan;32(1):41.e23-30. doi: 10.1016/j.urolonc.2013.04.013. Epub 2013 Aug 2. Urol Oncol. 2014. PMID: 23911680
-
The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.BJU Int. 2017 Jan;119(1):110-115. doi: 10.1111/bju.13602. Epub 2016 Aug 22. BJU Int. 2017. PMID: 27454454
-
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
-
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Nat Rev Urol. 2017. PMID: 27995937 Free PMC article. Review.
Cited by
-
Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study.Transl Androl Urol. 2024 Jul 31;13(7):1093-1103. doi: 10.21037/tau-24-90. Epub 2024 Jul 16. Transl Androl Urol. 2024. PMID: 39100847 Free PMC article.
-
Prostate cancer epidemiology and prognostic factors in the United States.Front Oncol. 2023 Oct 12;13:1142976. doi: 10.3389/fonc.2023.1142976. eCollection 2023. Front Oncol. 2023. PMID: 37901326 Free PMC article.
-
Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations.BMC Urol. 2022 Jun 25;22(1):91. doi: 10.1186/s12894-022-01045-0. BMC Urol. 2022. PMID: 35752822 Free PMC article.
-
Trends in Incidence of Metastatic Prostate Cancer in the US.JAMA Netw Open. 2022 Mar 1;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246. JAMA Netw Open. 2022. PMID: 35285916 Free PMC article.
-
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016.JAMA Netw Open. 2021 Aug 2;4(8):e2119568. doi: 10.1001/jamanetworkopen.2021.19568. JAMA Netw Open. 2021. PMID: 34351403 Free PMC article.
References
-
- Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–34. - PubMed
-
- Drazer MW, Prasad SM, Huo D, et al. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer 2014;120:1491–8. - PubMed
-
- Cohn JA, Wang CE, Lakeman JC, et al. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 2014;32:41.e23–30. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous